



A Tradition of Stewardship
A Commitment to Service

RECEIVED

DEC 13 2011

COUNTY OF NAPA
EXECUTIVE OFFICE

County Executive Office

1195 Third Street, Suite 310
Napa, CA 94559
www.countyofnapa.org

Main: (707) 253-4421
Fax: (707) 253-4176

Nancy Watt
County Executive Officer

December 5, 2011

PAUL A LASKAR

NAPA CA 94559

Re: Napa County Tobacco Advisory Board

Dear Mr. Laskar:

The term of your position representing Napa County Tobacco Advisory Board expires on January 31, 2012.

If you wish to request reappointment, please check the boxes below, sign where indicated, and return this letter to the County Executive Office. When the letter has been returned, your name will be forwarded to the Board of Supervisors for consideration for reappointment to another two-year term, as you have been a valued member of the Napa County Tobacco Advisory Board.

If any of the information on your last application for appointment has changed or is 5 years or older please contact the Napa County Executive's Office to obtain a new application, and submit the completed new application when returning this letter.

-
- ☒ Yes, I would like my name, this letter and application forwarded to the Board of Supervisors for possible reappointment to the Napa County Tobacco Advisory Board for the term commencing immediately and expiring January 31, 2014.
- ☒ I confirm by signing below that all the information on my application is current; or
- ☐ Some of the information on my prior application is no longer correct. A new application is attached.

A handwritten signature in black ink, appearing to read "Paul A. Laskar", written over a horizontal line.

SIGNATURE

A handwritten date in black ink, "10 December 2011", written over a horizontal line.

DATE

COUNTY EXECUTIVE OFFICE
1195 Third Street • Suite 310 • Napa, CA 94559 • (707) 253-4421
www.countyofnapa.org
FAX (707) 253-4176



RECEIVED

DEC 13 2011

County Executive Office
1195 Third Street, Room 310
Napa, CA 94559-3082
(707) 253-4421 FAX (707) 253-4176

RECEIVED

FEB 11 2010

eAFA

**APPLICATION FOR APPOINTMENT TO
BOARD, COMMISSION, COMMITTEE OR TASK FORCE**

A Tradition of Stewardship
A Commitment to Service

COUNTY OF NAPA
EXECUTIVE OFFICE

PLEASE TYPE OR PRINT (Complete pages 1 through 3)

*Application for Appointment to: (Name of Board, Commission, Committee or Task Force)

Tobacco Advisory Board

*Category of membership for which you are applying:
(This information can be found on the news release announcing the opening.
You may apply for more than one category if more than one position is open.)

Public member

*Supervisorial District in which you reside:

5

*Full Name

Paul A. Laskar

Date

2/8/2010

*Current Occupation (within the last twelve (12) months):

Consultant in pharmaceutical R&D

Current License (Professional or Occupational); Date of issue and/or expiration including status:

Registered Pharmacist, California (inactive)

Education/Experience: (A resume may be attached containing this and any other information that would be helpful to the Board in evaluating your application.)

Please see attached resume

Community participation (nature of activity and community location):

**Napa Youth Soccer League, assistant coach (1995-2005)
Judge, Science Fair, Alta Heights School, 2005 & 2006
Napa County Grand Jury, member, 2009-2010**

Other County Board/Commission/Committee on which you serve/have served:

None

Application for Appointment to: (Name of Board, Commission, Committee or Task Force)

Tobacco Advisory Board

Names, addresses and phone numbers of three (3) individuals familiar with your background:

*Name

Frederick F Giarrusso

*Address

*City

Napa

*State *Zip Code

CA**94558**

*Telephone

*Name

Kathy A Kenyon

*Address

*City

Napa

*State *Zip Code

CA**94558**

*Telephone

*Name

J Michael Delmage

*Address

*City

Napa

*State *Zip Code

CA**94558**

*Telephone

Name and occupation of spouse within the last 12 months, if married (for Conflict of Interest purposes):

Vinnie Laskar, pharmacist

*Please explain your reasons for wishing to serve and, in your opinion, how you feel you could contribute:

My desire to serve on the Tobacco Advisory Board derives from several factors:

- 1. Wish to provide service to my community where my family and I have lived for about 15 years;**
- 2. Actively contribute to reducing tobacco usage by Napa's residents of all ages;**
- 3. Belief that my healthcare background and experience in the pharmaceutical sciences will benefit the Board.**

Use of tobacco products has impacted me both close to home with family members as well as in my work experiences. I have witnessed firsthand within my family the addictive properties of smoking whether this is psychological or physiological. Both my parents smoked throughout my childhood. My father stopped smoking a few years before his death after having smoked for close to 50 years. My mother tried to stop smoking numerous times since as a nurse she knew the detrimental effects of this habit. She was unsuccessful until she died at which point she had been a smoker for more than 70 years. Fortunately, she was spared some of the more serious consequences of chronic smoking.

On a professional level, as a pharmacist, I have a good understanding of the dynamics of tobacco addictions. As a R&D professional within the pharmaceutical industry, I worked for a pharmaceutical company with a significant proportion of their sales for products used to treat the chronic respiratory effects of smoking, i.e., COPD (emphysema). As such I have reviewed the epidemiological evidence relating to the chronic health effects of tobacco usage as well as the societal costs in morbidity and healthcare dollars.

From the above I believe I have understanding on both subjective and objective levels about the hazards of tobacco usage and the ability, motivation, and energy to contribute to the work of the Board.

Application for Appointment to: (Name of Board, Commission, Committee or Task Force)

Tobacco Advisory Board

APPLICANTS APPOINTED BY THE BOARD OF SUPERVISORS WILL BE REQUIRED TO TAKE AN OATH OF OFFICE.

PLEASE NOTE THAT APPOINTEES MAY BE REQUIRED BY STATE LAW AND COUNTY CONFLICT OF INTEREST CODE TO FILE FINANCIAL DISCLOSURE STATEMENTS.

All applications will be kept on file for one year from the date of application

PERSONAL INFORMATION

The following information is provided in confidence to the extent that it will not be posted on the Internet, but may be used by the Board of Supervisors when making the appointment, or be used by the committee/commission/board/task force following appointment for purposes of communicating with the appointee.

Full Name

Paul A. Laskar

*e-mail Address

[REDACTED]

*Home Address

*Work Address

same as home address

*City

Napa

State

CA

*Zip Code

94559

*City

State Zip Code

[REDACTED]

[REDACTED]


[REDACTED]

*Telephone

Telephone

[REDACTED]

Please Read!

Paul A. Laskar, Ph.D.

Objective Employing extensive drug development experience provide consulting services in pharmaceutical R&D for start-up or established pharmaceutical company

Overview

- o Extensive drug development experience with variety of dosage forms from API and proof of principle through post-approval changes with start-up and established companies.
- o Prepared CMC sections for more than 6 NDAs/ANDAs, more than 10 INDs, and their ex-US regulatory counterparts; prepared Pharmaceutical Development Reports to support regulatory filings
- o Interacted with FDA in various formats: meetings at various stages of development, telephone conferences, and PAIs. Prepared, reviewed, and approved written responses to queries from FDA and European MOHs.
- o Built and managed lean, efficient, and effective pharmaceutical development departments for start-up and established companies
- o Developed and managed relationships with variety of contractors (API synthesis, drug product manufacture, clinical supply packaging and distribution, analytical chemistry support and stability assessment, and preclinical studies)
- o Established and nurtured effective relationships among R&D sites in Japan, Finland, and US. Served as R&D liaison between US and international sites

Experience

Oct, 2006 –
Present

President, Paul Laskar Associates, Inc, Napa, CA

Provide consulting services in areas of strategic CMC, pharmaceutical, and preclinical development plans and timelines; formulation development focusing on ophthalmic, dermatological, respiratory, and nasal drug products; stability assessment design, execution, and reporting; CRO/CMO identification, qualification, and management; API source evaluation; regulatory planning; clinical trial materials; and manufacturing process development and technology transfer. Prepare reports for regulatory filings from IND to NDA. Write and edit CMC sections for INDs, IMPDs, and FDA meetings. Write and edit Pharmaceutical Development Reports. Participate in interactions and meetings with regulatory agencies.

2003 -
Oct, 2006

Dey, L.P., Napa, CA**Senior Director, Pharmaceutical Development**

Lead formulation development, clinical trial materials supply, preclinical development, pilot operations, manufacturing process development, and technology transfer functions. Identify CROs for preclinical, clinical packaging and distribution, and contract manufacturing activities. Write CMC and preclinical documentation in support of 1 NDA, 2 ANDAs, 2 INDs, 2 sNDAs, 1 Canadian NDS, 1 IMPD, & 1 EU MAA. Prepare preclinical and CMC recommendations for in-license opportunities.

- Managed department of 11 professionals (3 Ph.D.; 7 BS) with a budget of >\$5000K (2006) in >10 development projects at various stages from preclinical to post-approval
- Prepared CMC sections for NDA, ANDAs, MAA/NDS, several INDs, sNDAs, and IMPD. Prepared preclinical sections for 1 NDA and several INDs
- Participated in several FDA meetings (preIND and end of Phase II)
- Prepared technical reviews of more than 10 in-license candidates annually

1994-2003

Santen, Inc., Napa, CA**Principal Director, Pharmaceuticals and Technology****Director/Vice President, Pharmaceutical Development**

Lead formulation development, analytical chemistry, clinical materials supply, stability assessment, preclinical function. Identify contractors to source manufacture of API and

drug products, prepare clinical trial kits, conduct analytical and stability studies, and perform preclinical studies. Work with peers at headquarters in Japan and European subsidiary to develop formulation and preclinical development strategies and execute technology transfer. Write and approve CMC and preclinical documentation for regulatory submissions. Interact with FDA. Prepare recommendations following CMC review of in-license candidates. Project leader for early stage and feasibility projects.

- Developed and managed project timelines and budgets (>\$3000K)
- Built lean and efficient department up to 10 persons (4 Ph.D.s; 1 DVM, 1 MS) despite evolving strategy for conducting pharmaceutical and preclinical development
- Prepared and/or directed preparation of CMC sections of 5 INDs, 1 CTX, 3 approved NDAs, 1 NDS, 2 MAAs, and 2 sNDAs.
- Directed development of systems to facilitate formulation development, technology transfer, stability assessment and clinical material tracking
- Helped develop and implement CMC and preclinical development strategy for several projects
- Served as CMC and preclinical liaison among R&D at Santen in Japan, US, and Finland
- Established and maintained relationships with Japanese and Finnish colleagues to facilitate progress of global preclinical and later stage development projects
- Prepared technical reviews of in-license candidates
- Guided process validation for API and drug products; participated in PAIs for API and drug product

1993-1994

CoCensys Inc., Irvine, CA**Director, Pharmaceutical Sciences**

Guide preformulation, formulation development, stability assessment, clinical materials supply, and research QC functions in early stage development of neurosteroid and glystatin compounds. Develop and manage relationships with consultants and contract analytical and manufacturing facilities for development projects.

- Wrote CMC sections for 2 INDs
- Developed documentation and systems to ensure compliance with cGMPs
- Initiated formulation development of 2 compounds (1 oral, 1 parenteral) in multiple presentations

1989-1993

Allergan/Herbert Laboratories, Irvine, CA**Manager/Director, Product Development, Herbert Laboratories**

Guide formulation development, analytical chemistry, stability assessment, and research QC functions for skin care division. Interact with other discovery and development departments, manufacturing, business development and marketing. Interact with FDA verbally and in person to gain registration approval. Develop and manage budget of ~\$1200K. Evaluate, recommend, and suggest products for potential acquisition.

- Grew department from 6 to 16 scientists and technicians
- Developed formulations to meet global requirements including parenterals, solid (immediate and extended release), and topicals
- Responsible for preparation of CMC sections of 11 INDs, NDAs and NDSs and a CTX
- Scaled up several products from laboratory through pilot to commercial scale manufacture; guided site transfer of three products from US to Europe
- Developed cost and timing estimates in project planning process
- Developed and managed relationships with several third party contractors

1988-1989

Procyte Corporation, Redmond, WA**Director, Pharmaceutical Development**

- Developed and initiated implementation of pharmaceutical development manpower strategy (recruited two section heads)
- Designed formulation and analytical chemistry laboratory
- Shared responsibility with one other person for preparation and filing of successful IND on lead compound

- Contributed to contract negotiations on joint venture with a major pharma company

1982-1988

Allergan, Inc., Irvine, CA**Scientist/Section Manager, Pharmaceuticals,**

- Brought two significant ophthalmic projects to registration status in Europe and US. Developed oral formulation, which enhanced bioavailability 2 ½-fold in animal model
- Formulated stable, elegant ocular solution product of 2 physically incompatible antimicrobials and developed a lyophilization cycle for its manufacture
- Supervised 3 BS personnel in up to 10 projects

1974-1982

1. **School of Pharmacy, Creighton University, Omaha, NE****Associate Professor of Pharmacy**2. **College of Pharmacy, University of Illinois-Medical Center, Chicago, IL****Assistant Professor of Pharmacy**

- Taught basic pharmaceuticals, pharmaceutical technology, pharmacokinetics, and therapeutics courses
- Developed self-instructional and videotape educational materials

Education**MBA**, University of California at Irvine, (General Management, International Management, Marketing)**Ph.D.**, Pharmaceutical Sciences, Oregon State University
(Minor: Biostatistics)**MS**, Pharmacy, University of Illinois – Medical Center**BS**, Pharmacy, University of Illinois – Medical Center**BA**, General Science (Chemistry, Biology), University of Rochester**Presentations**

SR Nadkarni & PA Laskar, "Comparison of Release Kinetics of Indomethacin from Gelucire Dispersions", AAPS, November 1992

S Matsumoto, et al., "Potential Irritation by Dermatological Vehicles Assessed with *In Vivo* and *In Vitro* Tests", AAPS, November 1992

SR Nadkarni & PA Laskar, "Investigation of Solid Dispersions of Indomethacin in Gelucires as Potential Sustained Release Systems", AAPS, November 1991

KA Kelley, PA Laskar, GD Ewing, SH Dromgoole, AA Sakr, JL Lichtin, "In Vitro Evaluation of Sunscreen Sustained Release Systems", AAPS, November 1991

Publications

KA Kelley, PA Laskar, GD Ewing, SH Dromgoole, JL Lichtin, & AA Sakr, "In Vitro Sun Protection Factor Evaluation of Sunscreen Products," J Soc Cosmet Sci, 44(3):139-151(May-June 1993)

PA Laskar & JW Ayres, "Degradation of Carmustine in Mixed Solvent and Nonaqueous Media", J Pharm Sci 66: 1976 (1977)

HR Manasse Jr. & PA Laskar, "Some Considerations Regarding Norm-Referenced and Criterion Referenced Testing in Pharmaceutical Education", Am J Pharm Educ 40:275 (1976)

JW Ayres, D Lorskulsint, A Lock, L Kuhl, PA Laskar, "Absorption and Distribution of Radioactivity from Suppositories Containing 3H-Benzocaine in Rats", J Pharm Sci 65:832 (1976)

JW Ayres & PA Laskar, "Diffusion of Benzocaine from Ointment Bases", J Pharm Sci 64:1402 (1974)

JW Ayres & PA Laskar, "Evaluation of Mathematical Models for Diffusion from Semisolids", J Pharm Sci 63:351 (1974)

JW Ayres & PA Laskar, "Student Experiments in Pharmaceutics: IV Additives, Chemical Incompatibilities, Kinetics, and the Arrhenius Equation", Am J Pharm Educ 38:58 (1974)

PA Laskar & RG Mrtek, "Synthesis and Biological Activity of Deuterio-benzyl-d₇-penicillin", J Pharm Sci 59:1727 (1970)

Patents

WO/1993/020796, "Method and Composition for Treating Acne", 28 October 1993, with S Nadkarni

Application (US20050009836), "Ophthalmic Composition Containing Quinolones & Method of Use," with SD Hickok

Other

Registered Pharmacist: California and Illinois (inactive)

Western Region, AAPS: Fundraising Chairperson, 1992-1993; Academic Award Chairperson, 1991; Publicity Chairperson, 1989-1991; Meeting Chairperson, 1988; Meeting Co-Chairperson, 1987; Program Chairperson, 1986; Poster Session & Publicity Chairperson, 1985

AAPS Provisional Biotechnology Section: Chairperson, Program Committee, 1988

Graduate student advisor & adjunct faculty, Univ. Cincinnati, College of Pharmacy, 1990-1993

Author/co-author, Instructional Videotapes, "Extemporaneous Preparation of Hard Gelatin Capsules," Extemporaneous Preparation of Ointments," and Extemporaneous Preparation of Suppositories," UIMC, 1979

